comparemela.com

Latest Breaking News On - Janssen emea - Page 2 : comparemela.com

First Results with Erdafitinib-Releasing Intravesical

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery.

Comunidad autonoma de catalunaRegion flamandeIndianj urolJanssen cilag gmbJanssen pharmaceuticaJeffrey infanteMartin vogelUrology care foundationJanssen research developmentNone of the janssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonEuropean society for medical oncologyAstex therapeuticsOncology early clinical developmentTranslational researchAstex announces new drug discovery alliance

Results from Phase 2 THOR-2 Study Showed Improved Rates of

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical.

Region flamandeUnited kingdomJanssen cilag gmbIndianj urolKiran patelJames wf cattoMartin vogelJanssen pharmaceuticaAstex announces new drug discovery allianceUniversity of sheffieldClinical developmentJanssen researchNone of the janssen pharmaceutical companiesExchange commissionJanssen pharmaceutical companiesDrug administration

New Safety Data Suggests SPRAVATO®▼ (Esketamine Nasal

Beerse, Belgium, Oct. 08, 2023 (GLOBE NEWSWIRE) The new safety data is from the ESCAPE-TRD Phase 3b study1Additional findings from this study showed.

United kingdomComunidad autonoma de catalunaRegion flamandeClin psychopharmacolClin neurosciEduard vietaEuropean medicines agencyDrug administrationPatient health questionnaireExchange commissionNone of the janssen pharmaceutical companiesPsychology service of the hospital clEuropean college of neuropsychopharmacology congressJanssen cilag ltdWorld health organizationJanssen cilag international

Janssen Submits Marketing Authorisation Application to the

Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor,1 will become the.

United statesRegion flamandeJanssen pharmaceuticaTanakam sonpavdeKiran patelJanssen cilag gmbMartin vogelClinical developmentJanssen pharmaceutical companiesAstex therapeuticsAstex announces new drug discovery allianceAmerican society of clinical oncologyNone of the janssen pharmaceutical companiesCompanies of johnsonJanssen research development in phaseJanssen research development

Janssen Receives Positive CHMP Opinions for Novel

Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to.

United statesRegion flamandeUnited kingdomSen zhuangEdmond chanCommittee for medicinal products human useNone of the janssen pharmaceutical companiesAmerican society of clinical oncologyEuropean medicines agencyEuropean hematology associationDrug administrationEuropean commissionJanssen research developmentJanssen pharmaceutical companies of johnsonExchange commissionClinical research

vimarsana © 2020. All Rights Reserved.